Dermatology Debates: The Derms on Drugs Try to Change Minds
Description
Welcome to the first-ever Derms on Drugs Debate! Our brave hosts tackle three of the hottest—and most controversial—questions in the field:
Castle Gene Expression Profile in Melanoma: Should dermatologists use it for almost every melanoma, just those “close to 1 mm,” or leave it to the oncologists?
Zoryve, VTAMA and Opzelura: All great drugs, but if you could only keep one, which would it be? Our hosts go head-to-head to defend their picks.
The Next Game Changer in Dermatology: Will it be AI-powered skin cancer diagnosis, BTK inhibitors, or the first generic oral JAK? Hear our predictions and the cases for each.
Whether you’re a dermatology provider, researcher, or pharma professional, you’ll get expert insights, practical takeaways, and plenty of lively debate—Derms on Drugs style.
Tune in for clinical pearls, bold opinions, and a fresh look at the future of dermatology. Don’t miss out—hit play and join the debate!
United States
